Originally posted by: Ryan McBride 1/10/11
According to information released on the web, Civitas says it has secured $20 million in a Series A round of funding, which is primarily intended to back development of the startup’s technology for treating patients with Parkinson’s disease, says Glenn Batchelder, a founder and CEO of the firm.The firm sees such benefit potential for patients with Parkinson’s.Patients with the neurological disease have trouble moving, especially when typically oral drugs such as L-dopa and other pills fall short on keeping steady levels of a neurotransmitter called dopamine in their system.Parkinson’s can also rob people of their normal capacity to swallow, he says, and that too can be overcome with inhaled delivery.The company isn’t saying which drugs it plans to deliver in the inhaled particles, including in the Parkinson’s program. Yet the firm hopes to begin initial clinical studies in humans in early 2012 for the Parkinson’s treatment and have some validation of that program by the end of the year.
To learn more about this topic or to read the full article, please visit the link below.
http://www.xconomy.com/boston/2011/01/10/alkermes-finds-new-home-for-inhaled-drug-delivery-tech-with-civitas-spinout/
The Parkinson Research Foundation is a nonprofit health organization providing Parkinson's research, information and advocacy. The mission of the organization is to cure Parkinson's and to improve the lives of all people affected by the disease. To fulfill this mission, the Parkinson Research Foundation funds research, publishes scientific findings, provides funding for information and other services to people with Parkinson's, their families, health care professionals and to the general public. The Parkinson Research Foundation is designated as a 501(c)(3) charity by the Internal Revenue Service.
To learn more about the Parkinson Research Foundation, to help support our mission, or learn how you can get involved please visit us at http://www.parkinsonresearchfoundation.org
No comments:
Post a Comment